US2012195904A1PendingUtilityA1

METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES

Assignee: KIKLY KRISTINE KAYPriority: Aug 16, 2001Filed: Apr 11, 2012Published: Aug 2, 2012
Est. expiryAug 16, 2021(expired)· nominal 20-yr term from priority
A61P 37/08A61P 37/02A61P 43/00A61P 37/00A61P 35/00A61P 29/00A61P 31/04A61P 17/02A61P 11/06A61P 1/04A61P 17/06A61P 15/00A61P 19/02C07K 2317/73C07K 2317/33C07K 2317/21C07K 2317/53C07K 2317/92C07K 2317/565A01K 2217/05C07K 2317/34A61K 2039/505C07K 2317/76C07K 16/2875C07K 16/24
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., K D =10 −8 M or less), a slow off rate for TNFSF13b dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.

Claims

exact text as granted — not AI-modified
1 - 41 . (canceled) 
     
     
         42 . A method of treating a human patient suffering from rheumatoid arthritis comprising administering to the said patient an anti-hTNFSF13b human antibody comprising SEQ ID NO: 17 and SEQ ID NO: 19. 
     
     
         43 . The method of treating a human patient suffering from rheumatoid arthritis comprising administering to the said patient an anti-hTNFSF13b human antibody comprising SEQ ID NO: 18 and SEQ ID NO: 19.

Join the waitlist — get patent alerts

Track US2012195904A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.